Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2023-05-18 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-05-18 English
Letter from successor auditor.pdf
Regulatory Filings
2023-05-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of new dental products by Rapid Dose Therapeutics. It contains no financial data, no regulatory filing references, no meeting materials, no voting results, no management or board changes, no earnings or interim reports, and no audit or legal information. It is a corporate announcement about product launch and marketing events. Therefore, it does not fit into any specific financial or regulatory filing category. The best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2023-05-10 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the resumption of trading of Rapid Dose Therapeutics Corp. shares on the Canadian Securities Exchange. It contains no financial statements, no detailed financial data, no management discussion or analysis, and no regulatory form references. The document is short (3745 characters) and primarily serves as a trading status update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is not a report publication announcement since it does not mention any report being published or attached. The content is a general regulatory announcement about trading status, which fits best under Regulatory Filings (RNS).
2023-05-04 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the revocation of a cease trade order by the Ontario Securities Commission (OSC) against Rapid Dose Therapeutics Corp. It references the filing of annual and interim financial statements and related documents but does not contain the financial statements or detailed financial data itself. The document mainly informs about regulatory compliance status and the resumption of trading. It is not the actual annual or interim report, nor a certification letter. The document is about regulatory status and compliance updates, fitting best under Regulatory Filings (RNS). The document length is 5557 characters, which is relatively short and consistent with an announcement rather than a full report.
2023-05-02 English
Statement of executive compensation (form 51-102F6V) - English.pdf
Remuneration Information Classification · 95% confidence The document is titled 'Form 51-102F6V Statement of Executive Compensation' and contains detailed discussion and analysis of executive compensation, including base fees, short-term incentives, long-term incentives (stock options), benefits, and the stock option plan. It references regulatory requirements under National Instrument 51-102 Continuous Disclosure Obligations, which is a Canadian regulatory framework for venture issuers. The content focuses on executive compensation details rather than financial results, governance structure, or other report types. This matches the description of a Remuneration Information filing, which details compensation for top executives and directors. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2023-04-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.